|
US4450150A
(en)
|
1973-05-17 |
1984-05-22 |
Arthur D. Little, Inc. |
Biodegradable, implantable drug delivery depots, and method for preparing and using the same
|
|
US4232027A
(en)
|
1979-01-29 |
1980-11-04 |
E. R. Squibb & Sons, Inc. |
1,2-Dihydro-2-oxo-4-phenyl-3-quinolinecarbonitrile derivatives
|
|
GB2116183B
(en)
|
1982-03-03 |
1985-06-05 |
Genentech Inc |
Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
|
|
JPS63502716A
(ja)
|
1986-03-07 |
1988-10-13 |
マサチューセッツ・インステチュート・オブ・テクノロジー |
糖タンパク安定性の強化方法
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
WO1988009344A1
(fr)
|
1987-05-21 |
1988-12-01 |
Creative Biomolecules, Inc. |
Proteines mutifonctionnelles a cible predeterminee
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
JP2762522B2
(ja)
|
1989-03-06 |
1998-06-04 |
藤沢薬品工業株式会社 |
血管新生阻害剤
|
|
GB8912336D0
(en)
|
1989-05-30 |
1989-07-12 |
Smithkline Beckman Intercredit |
Compounds
|
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
|
EP1690935A3
(fr)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Génération d'anticorps xenogéniques
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
JP2938569B2
(ja)
|
1990-08-29 |
1999-08-23 |
ジェンファーム インターナショナル，インコーポレイティド |
異種免疫グロブリンを作る方法及びトランスジェニックマウス
|
|
US6770274B1
(en)
|
1990-09-14 |
2004-08-03 |
The General Hospital Corporation |
Viral mutant HSV mediated destruction of neoplastic cells
|
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
|
US5892112A
(en)
|
1990-11-21 |
1999-04-06 |
Glycomed Incorporated |
Process for preparing synthetic matrix metalloprotease inhibitors
|
|
US5780279A
(en)
|
1990-12-03 |
1998-07-14 |
Genentech, Inc. |
Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
|
|
WO1992009690A2
(fr)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
|
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
|
CA2066898A1
(fr)
|
1991-04-29 |
1992-10-30 |
Chuan Shih |
Composes pharmaceutiques
|
|
JP3266311B2
(ja)
|
1991-05-02 |
2002-03-18 |
生化学工業株式会社 |
新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
|
|
EP0584222B1
(fr)
|
1991-05-10 |
1997-10-08 |
Rhone-Poulenc Rorer International (Holdings) Inc. |
Composes aryle et heteroaryle bis monocycliques et/ou bicycliques qui inhibent la tyrosine kinase d'un recepteur du egf et/ou du pdgf
|
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
|
US5871907A
(en)
|
1991-05-15 |
1999-02-16 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
US5858657A
(en)
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
|
DE4221054A1
(de)
|
1992-06-30 |
1994-01-05 |
Herbst Bremer Goldschlaegerei |
Präparat zur prophylaktischen und therapeutischen Behandlung von Karies sowie Verfahren zum Herstellen desselben
|
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
|
PT669929E
(pt)
|
1992-11-13 |
2007-04-30 |
Immunex Corp |
Ligando de elk, uma citoquina
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
US5855885A
(en)
|
1993-01-22 |
1999-01-05 |
Smith; Rodger |
Isolation and production of catalytic antibodies using phage technology
|
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
|
EP0672035A1
(fr)
|
1993-10-01 |
1995-09-20 |
Novartis AG |
Derives pyrimidineamine et leurs procedes de preparation
|
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
CA2175215C
(fr)
|
1993-11-19 |
2008-06-03 |
Yat Sun Or |
Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs
|
|
PL314238A1
(en)
|
1993-12-17 |
1996-09-02 |
Sandoz Ltd |
Rapamycin derivatives
|
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
WO1995024190A2
(fr)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
|
|
WO1995028484A1
(fr)
|
1994-04-15 |
1995-10-26 |
Amgen Inc. |
Nouvelles proteines tyrosine kinases receptrices analogues a l'eph, du type hek5, hek7, hek8, hek11
|
|
ES2109796T3
(es)
|
1994-05-03 |
1998-01-16 |
Ciba Geigy Ag |
Derivados de pirrolopirimidilo con efecto antiproliferante.
|
|
US5585096A
(en)
|
1994-06-23 |
1996-12-17 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
|
US6699468B1
(en)
|
1994-06-23 |
2004-03-02 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
|
US5728379A
(en)
|
1994-06-23 |
1998-03-17 |
Georgetown University |
Tumor- or cell-specific herpes simplex virus replication
|
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
CA2216796C
(fr)
|
1995-03-30 |
2003-09-02 |
Pfizer Inc. |
Derives de quinazoline
|
|
JP4249804B2
(ja)
|
1995-04-03 |
2009-04-08 |
ノバルティス・アクチエンゲゼルシャフト |
ピラゾール誘導体およびその製造法
|
|
MX9708026A
(es)
|
1995-04-20 |
1997-11-29 |
Pfizer |
Derivados del acido arislfulfonil hidroxamico, composiciones que los contienen y uso de los mismos.
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US5702892A
(en)
|
1995-05-09 |
1997-12-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Phage-display of immunoglobulin heavy chain libraries
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
ATE228135T1
(de)
|
1995-06-09 |
2002-12-15 |
Novartis Erfind Verwalt Gmbh |
Rapamycinderivate
|
|
KR100437582B1
(ko)
|
1995-07-06 |
2004-12-17 |
노파르티스 아게 |
피롤로피리미딘및그들의제조방법
|
|
DE19534177A1
(de)
|
1995-09-15 |
1997-03-20 |
Merck Patent Gmbh |
Cyclische Adhäsionsinhibitoren
|
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
ES2183905T3
(es)
|
1995-12-20 |
2003-04-01 |
Hoffmann La Roche |
Inhibidores de metaloproteasa de matriz.
|
|
ES2177925T3
(es)
|
1996-01-23 |
2002-12-16 |
Novartis Ag |
Pirrolopirimidinas y procedimientos para su preparacion.
|
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
ES2203793T3
(es)
|
1996-03-15 |
2004-04-16 |
Novartis Ag |
N-7-heterociclil-pirrolo(2,3-d)pirimidinas y su empleo.
|
|
US5714352A
(en)
|
1996-03-20 |
1998-02-03 |
Xenotech Incorporated |
Directed switch-mediated DNA recombination
|
|
EA001595B1
(ru)
|
1996-04-12 |
2001-06-25 |
Варнер-Ламберт Компани |
Необратимые ингибиторы тирозинкиназ
|
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
|
EP0907642B1
(fr)
|
1996-06-24 |
2005-11-02 |
Pfizer Inc. |
Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
|
|
AU735648B2
(en)
|
1996-07-12 |
2001-07-12 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
|
EP0818442A3
(fr)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
|
|
AR007857A1
(es)
|
1996-07-13 |
1999-11-24 |
Glaxo Group Ltd |
Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
|
|
ID19430A
(id)
|
1996-07-13 |
1998-07-09 |
Glaxo Group Ltd |
Senyawa senyawa heterosiklik
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
IL127567A0
(en)
|
1996-07-18 |
1999-10-28 |
Pfizer |
Phosphinate based inhibitors of matrix metalloproteases
|
|
US5824318A
(en)
|
1996-07-24 |
1998-10-20 |
American Cyanamid Company |
Avirulent herpetic viruses useful as tumoricidal agents and vaccines
|
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
DE69738749D1
(de)
|
1996-08-16 |
2008-07-17 |
Schering Corp |
Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
|
|
JP2000501423A
(ja)
|
1996-08-23 |
2000-02-08 |
ファイザー インク． |
アリールスルホニルアミノヒドロキサム酸誘導体
|
|
DE69738468T2
(de)
|
1996-08-23 |
2009-01-08 |
Novartis Ag |
Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
|
|
AU4779897A
(en)
|
1996-10-02 |
1998-04-24 |
Novartis Ag |
Fused pyrazole derivatives and processes for their preparation
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
WO1998014450A1
(fr)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Derives de pyrimidine et procedes de preparation de ces derniers
|
|
EP0837063A1
(fr)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
Dérivés de 4-aminoquinazoline
|
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
|
ES2301183T3
(es)
|
1996-12-03 |
2008-06-16 |
Amgen Fremont Inc. |
Anticuerpo completamente humano que se une al receptor del egfr.
|
|
PT950059E
(pt)
|
1997-01-06 |
2004-10-29 |
Pfizer |
Derivados de sulfona ciclicos
|
|
ES2202796T3
(es)
|
1997-02-03 |
2004-04-01 |
Pfizer Products Inc. |
Derivados de acidos arilsulfonilaminohidroxamicos.
|
|
ES2301194T3
(es)
|
1997-02-05 |
2008-06-16 |
Warner-Lambert Company Llc |
Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
|
|
EP0966438A1
(fr)
|
1997-02-07 |
1999-12-29 |
Pfizer Inc. |
Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices
|
|
CA2280151C
(fr)
|
1997-02-11 |
2005-12-13 |
Pfizer Inc. |
Derives de l'acide arylsulfonylhydroxamique
|
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
|
US6057098A
(en)
|
1997-04-04 |
2000-05-02 |
Biosite Diagnostics, Inc. |
Polyvalent display libraries
|
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
|
AU8689298A
(en)
|
1997-08-05 |
1999-03-01 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
|
EA002490B1
(ru)
|
1997-08-08 |
2002-06-27 |
Пфайзер Продактс Инк. |
Производные арилоксиарилсульфониламиногидроксамовой кислоты
|
|
US6379674B1
(en)
|
1997-08-12 |
2002-04-30 |
Georgetown University |
Use of herpes vectors for tumor therapy
|
|
JP2001520039A
(ja)
|
1997-10-21 |
2001-10-30 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
|
WO1999040196A1
(fr)
|
1998-02-09 |
1999-08-12 |
Genentech, Inc. |
Nouveaux homologues recepteurs du facteur necrosant des tumeurs et acides nucleiques codant ceux-ci
|
|
CA2320193A1
(fr)
|
1998-02-10 |
1999-08-19 |
Welfide Corporation |
Preparations a liberation controlee
|
|
CA2322311C
(fr)
|
1998-03-04 |
2009-10-13 |
Bristol-Myers Squibb Company |
Inhibiteurs de la proteine tyrosine kinase, a base d'imidazopyrazine a substitution heterocyclo
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
WO1999054440A1
(fr)
|
1998-04-21 |
1999-10-28 |
Micromet Gesellschaft Für Biomedizinische Forschung Mbh |
Polypeptides specifiques a cd19 et cd3 et leurs utilisations
|
|
IL139934A
(en)
|
1998-05-29 |
2007-10-31 |
Sugen Inc |
History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them
|
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
|
WO2000002871A1
(fr)
|
1998-07-10 |
2000-01-20 |
Merck & Co., Inc. |
Nouveaux inhibiteurs de l'angiogenese
|
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
|
AU760020B2
(en)
|
1998-08-31 |
2003-05-08 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
|
DE69915004T2
(de)
|
1998-11-05 |
2004-09-09 |
Pfizer Products Inc., Groton |
5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
|
|
GB2344287A
(en)
|
1998-12-03 |
2000-06-07 |
Ferring Bv |
Controlled release pharmaceutical formulation
|
|
WO2000040734A1
(fr)
|
1998-12-31 |
2000-07-13 |
Arch Development Corporation |
Virus de l'herpes simplex recombinant utile dans le traitement des maladies neoplasiques
|
|
ATE538794T1
(de)
|
1999-01-13 |
2012-01-15 |
Bayer Healthcare Llc |
Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
|
|
AU2905199A
(en)
|
1999-03-15 |
2000-10-04 |
Trustees Of The University Of Pennsylvania, The |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
AU766081B2
(en)
|
1999-03-30 |
2003-10-09 |
Novartis Ag |
Phthalazine derivatives for treating inflammatory diseases
|
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
|
WO2000075323A1
(fr)
|
1999-06-07 |
2000-12-14 |
Immunex Corporation |
Antagonistes tek
|
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
|
US6764675B1
(en)
|
1999-06-08 |
2004-07-20 |
The Uab Research Foundation |
Herpes simplex virus expressing foreign genes and method for treating cancers therewith
|
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
|
ES2295040T3
(es)
|
1999-07-12 |
2008-04-16 |
Genentech, Inc. |
Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
|
|
IL147803A0
(en)
|
1999-08-24 |
2002-08-14 |
Ariad Gene Therapeutics Inc |
28-epirapalogs
|
|
IL149034A0
(en)
|
1999-11-05 |
2002-11-10 |
Astrazeneca Ab |
Quinazoline derivatives as vegf inhibitors
|
|
ES2367007T3
(es)
|
1999-11-24 |
2011-10-27 |
Sugen, Inc. |
Derivados de indolinona ionizables y su uso como ligandos de ptk.
|
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
|
JP4921669B2
(ja)
|
2000-01-21 |
2012-04-25 |
バイオヴェックス リミテッド |
ウイルス株
|
|
EP1257289A1
(fr)
|
2000-02-08 |
2002-11-20 |
The Penn State Research Foundation |
Utilisation du recepteur de l'interleukine 13, sous-unite alpha 2, dans l'immunotherapie
|
|
AU4721901A
(en)
|
2000-02-25 |
2001-09-03 |
Immunex Corp |
Integrin antagonists
|
|
US6960614B2
(en)
|
2000-07-19 |
2005-11-01 |
Warner-Lambert Company |
Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
|
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
|
IL156306A0
(en)
|
2000-12-21 |
2004-01-04 |
Glaxo Group Ltd |
Pyrimidineamines as angiogenesis modulators
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
|
JP4212897B2
(ja)
|
2001-03-27 |
2009-01-21 |
具紀 藤堂 |
ウイルスおよび治療法におけるそれらの使用
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
JP2005512044A
(ja)
|
2001-12-03 |
2005-04-28 |
アブジェニックス・インコーポレーテッド |
結合特性に基づく抗体分類
|
|
JP2002233610A
(ja)
|
2002-02-18 |
2002-08-20 |
Olympia:Kk |
スロットマシン
|
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
|
ATE458534T1
(de)
|
2002-10-04 |
2010-03-15 |
Microchips Inc |
Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
|
|
CN1513993A
(zh)
|
2002-12-31 |
2004-07-21 |
北京博泰迪生物工程科技开发有限公司 |
中国人基因组cDNA文库白细胞介素21的编码基因序列及其蛋白质的氨基酸序列
|
|
WO2004063195A1
(fr)
|
2003-01-03 |
2004-07-29 |
Sloan-Kettering Institute For Cancer Research |
Inhibiteurs de kinases a base de pyridopyrimidine
|
|
US7618632B2
(en)
|
2003-05-23 |
2009-11-17 |
Wyeth |
Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
|
|
RU2005141512A
(ru)
|
2003-05-31 |
2007-07-20 |
Микромет Аг (De) |
Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
|
|
AU2004255340B2
(en)
|
2003-07-08 |
2008-05-01 |
Novartis Ag |
Use of rapamycin and rapamycin derivatives for the treatment of bone loss
|
|
EP1648900A4
(fr)
|
2003-07-11 |
2010-02-10 |
Ariad Pharma Inc |
Macrocycles contenant du phosphore
|
|
EP1660126A1
(fr)
|
2003-07-11 |
2006-05-31 |
Schering Corporation |
Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer
|
|
AR045134A1
(es)
|
2003-07-29 |
2005-10-19 |
Smithkline Beecham Plc |
Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
|
|
MXJL06000006A
(es)
|
2003-08-22 |
2006-05-04 |
Avanir Pharmaceuticals |
Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre.
|
|
EP2292664B1
(fr)
|
2003-10-16 |
2016-11-23 |
Amgen Research (Munich) GmbH |
Molécules des-immunisées liant le CD3 multispecifiques
|
|
WO2005055808A2
(fr)
|
2003-12-02 |
2005-06-23 |
Genzyme Corporation |
Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
|
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
|
WO2005118635A2
(fr)
|
2004-06-03 |
2005-12-15 |
Novimmune S.A. |
Anticorps anti-cd3 et leurs methodes d'utilisation
|
|
EP1765402A2
(fr)
|
2004-06-04 |
2007-03-28 |
Duke University |
Methodes et compositions ameliorant l'immunite par depletion in vivo de l'activite cellulaire immunosuppressive
|
|
US7731952B2
(en)
|
2004-06-24 |
2010-06-08 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
BRPI0513915A
(pt)
|
2004-08-26 |
2008-05-20 |
Pfizer |
compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
|
|
CN101039952A
(zh)
|
2004-10-13 |
2007-09-19 |
惠氏公司 |
作为pi3k抑制剂的17－羟基渥曼青霉素类似物
|
|
AU2005295441B2
(en)
|
2004-10-18 |
2009-04-23 |
Amgen, Inc. |
Thiadiazole compounds and methods of use
|
|
CA2599925A1
(fr)
|
2005-03-14 |
2006-09-21 |
Merck & Co., Inc. |
Antagonistes du recepteur du cgrp
|
|
CA2602777C
(fr)
|
2005-03-25 |
2018-12-11 |
Tolerrx, Inc. |
Molecules de liaison gitr et leurs utilisations
|
|
EP2439273B1
(fr)
|
2005-05-09 |
2019-02-27 |
Ono Pharmaceutical Co., Ltd. |
Anticorps monoclonaux humains pour mort programmée 1 (PD-1) et procédés de traitement du cancer à l'aide d'anticorps anti-PD-1 seuls ou combinés à d'autres formulations immunothérapeutiques
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
AU2006293620A1
(en)
|
2005-09-20 |
2007-03-29 |
Pfizer Products Inc. |
Dosage forms and methods of treatment using a tyrosine kinase inhibitor
|
|
EP1981884B1
(fr)
|
2006-01-18 |
2012-06-13 |
Amgen, Inc |
Composés thiazoliques comme inhibiteurs de protéine kinase b
|
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
|
EP2114949A1
(fr)
|
2006-12-07 |
2009-11-11 |
F.Hoffmann-La Roche Ag |
Composés inhibant la phosphoinositide 3 kinase et procédés d'utilisation
|
|
CN101230335B
(zh)
|
2007-01-22 |
2010-08-11 |
北京奥源和力生物技术有限公司 |
单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
|
|
CN101230334B
(zh)
|
2007-01-22 |
2011-06-01 |
北京奥源和力生物技术有限公司 |
单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
|
|
CN101715453B
(zh)
|
2007-03-23 |
2012-06-27 |
安姆根有限公司 |
杂环化合物及其应用
|
|
MX2009010050A
(es)
|
2007-03-23 |
2009-10-12 |
Amgen Inc |
Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
|
|
US7919498B2
(en)
|
2007-03-23 |
2011-04-05 |
Amgen Inc. |
Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors
|
|
RU2561457C2
(ru)
|
2007-04-03 |
2015-08-27 |
Эмджен Рисерч (Мьюник) Гмбх |
Cd3-эпсилон-связывающий домен с межвидовой специфичностью
|
|
PT2520590T
(pt)
|
2007-04-03 |
2018-11-14 |
Amgen Res Munich Gmbh |
Domínio de ligação específico de espécies cruzadas
|
|
NZ580700A
(en)
|
2007-04-19 |
2012-01-12 |
Dong A Pharm Co Ltd |
A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
|
|
WO2008153947A2
(fr)
|
2007-06-07 |
2008-12-18 |
Amgen Inc. |
Modulateurs de la raf kinase et leurs méthodes d'utilisation
|
|
DK2175884T3
(en)
|
2007-07-12 |
2016-09-26 |
Gitr Inc |
Combination USING GITR BINDING MOLECULES
|
|
CA2693473A1
(fr)
|
2007-07-17 |
2009-01-22 |
Amgen Inc. |
Thiadiazoles modulateurs de l'activite de pkb
|
|
AU2008276521B2
(en)
|
2007-07-17 |
2011-11-03 |
Amgen Inc. |
Heterocyclic modulators of PKB
|
|
JP5561702B2
(ja)
|
2007-08-02 |
2014-07-30 |
アムジエン・インコーポレーテツド |
Ｐｉ３キナーゼ調節剤および使用方法
|
|
JP5658565B2
(ja)
|
2007-09-12 |
2015-01-28 |
ジェネンテック， インコーポレイテッド |
ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法
|
|
JP5348725B2
(ja)
|
2007-10-25 |
2013-11-20 |
ジェネンテック， インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
|
MX2010006457A
(es)
|
2007-12-19 |
2010-07-05 |
Amgen Inc |
Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
|
|
US7820665B2
(en)
|
2007-12-19 |
2010-10-26 |
Amgen Inc. |
Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
JP5530422B2
(ja)
|
2008-04-07 |
2014-06-25 |
アムジエン・インコーポレーテツド |
細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン
|
|
WO2009127691A1
(fr)
|
2008-04-17 |
2009-10-22 |
Ablynx N.V. |
Peptides capables de se lier à des protéines sériques et composés, constructions et polypeptides les comprenant
|
|
MX315904B
(es)
|
2008-05-30 |
2013-11-29 |
Amgen Inc |
Inhibidores de fosfoinosituro-3 cinasa.
|
|
US20110177070A1
(en)
|
2008-07-02 |
2011-07-21 |
Emergent Product Development Seatlle, LLC |
TGF-Beta Antagonist Multi-Target Binding Proteins
|
|
US8586023B2
(en)
|
2008-09-12 |
2013-11-19 |
Mie University |
Cell capable of expressing exogenous GITR ligand
|
|
DK2356153T3
(en)
|
2008-10-01 |
2016-07-04 |
Amgen Res Munich Gmbh |
Bispecific single CHAIN PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
|
|
WO2010083246A1
(fr)
|
2009-01-15 |
2010-07-22 |
Amgen Inc. |
Thiazoles substitués par fluoroisoquinoléine et leurs méthodes d'application
|
|
AU2010216239B2
(en)
|
2009-02-18 |
2012-06-14 |
Amgen Inc. |
Indole/benzimidazole compounds as mTOR kinase inhibitors
|
|
US20120107267A1
(en)
|
2009-03-11 |
2012-05-03 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
|
CA2755285C
(fr)
|
2009-03-20 |
2014-02-11 |
Yunxin Y. Bo |
Inhibiteurs de pi3 kinase
|
|
UY32582A
(es)
|
2009-04-28 |
2010-11-30 |
Amgen Inc |
Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
|
|
MX2011012037A
(es)
|
2009-05-13 |
2012-02-28 |
Amgen Inc |
Compuestos de heteroarilo como inhibidores de pikk.
|
|
UY32743A
(es)
|
2009-06-25 |
2010-12-31 |
Amgen Inc |
Compuestos heterocíclicos y sus usos
|
|
UY32742A
(es)
|
2009-06-25 |
2010-12-31 |
Amgen Inc |
Compuestos heterocíclicos y sus usos
|
|
CA2765817A1
(fr)
|
2009-06-25 |
2010-12-29 |
Amgen Inc. |
Derives 4h-pyrido[1,2-a]pyrimidin-4-one en tant qu'inhibiteurs de pi3k
|
|
WO2010151737A2
(fr)
|
2009-06-25 |
2010-12-29 |
Amgen Inc. |
Composés hétérocycliques et leurs utilisations
|
|
ES2865648T3
(es)
|
2009-06-26 |
2021-10-15 |
Regeneron Pharma |
Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa
|
|
SG178991A1
(en)
|
2009-09-03 |
2012-04-27 |
Schering Corp |
Anti-gitr antibodies
|
|
ES2528485T3
(es)
|
2009-09-11 |
2015-02-10 |
Amgen, Inc |
N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina para su uso en el tratamiento del cáncer resistente a agentes antimitóticos
|
|
JP2013509170A
(ja)
|
2009-10-30 |
2013-03-14 |
ノボザイムス バイオファーマ デーコー アクティーゼルスカブ |
アルブミン変異体
|
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
|
PT2519543T
(pt)
|
2009-12-29 |
2016-10-07 |
Emergent Product Dev Seattle |
Proteínas de ligação de heterodímero e suas utilizações
|
|
CN103347893A
(zh)
|
2010-11-01 |
2013-10-09 |
诺维信生物制药丹麦公司 |
白蛋白变体
|
|
CA2829628A1
(fr)
|
2011-03-11 |
2012-09-20 |
Amgen Inc. |
Procede d'analyse mutationnelle correlee pour ameliorer des anticorps therapeutiques
|
|
WO2012142498A2
(fr)
|
2011-04-13 |
2012-10-18 |
Innovimmune Biotherapeutics, Inc. |
Facteurs d'inhibition de la migration des macrophages (mif) et leurs utilisations
|
|
KR20140027307A
(ko)
|
2011-05-05 |
2014-03-06 |
노보자임스 바이오파마 디케이 에이/에스 |
알부민 변이체
|
|
WO2013006795A2
(fr)
|
2011-07-07 |
2013-01-10 |
Humanitas International Foundation |
Compositions antivirales et leurs méthodes d'utilisation
|
|
SMT201900033T1
(it)
|
2011-09-08 |
2019-02-28 |
Univ New York |
Virus herpes simplex oncolitico e suoi usi terapeutici
|
|
WO2013039954A1
(fr)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anticorps anti-gitr
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
EP2780364A2
(fr)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Protéines ayant une demi-vie et d'autres propriétés améliorées
|
|
WO2013109904A1
(fr)
|
2012-01-19 |
2013-07-25 |
University Of Miami |
Compositions, procédés et série de traitements contre le cancer et des maladies auto-immunes
|
|
WO2013135896A1
(fr)
|
2012-03-16 |
2013-09-19 |
Novozymes Biopharma Dk A/S |
Variants d'albumine
|
|
CN104379563B
(zh)
|
2012-04-10 |
2018-12-21 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|
|
WO2013169734A1
(fr)
|
2012-05-07 |
2013-11-14 |
Amgen Inc. |
Anticorps anti-érythropoïétine
|
|
WO2013169693A1
(fr)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Méthodes destinées à traiter le cancer à l'aide d'un polypeptide il-21 et d'un anticorps anti-pd-1
|
|
EP2882746B1
(fr)
|
2012-08-07 |
2016-12-07 |
Merck Patent GmbH |
Dérivés de pyridopyrimidine en tant qu'inhibiteurs de protéine kinase
|
|
RU2670063C2
(ru)
|
2012-11-08 |
2018-10-17 |
Альбумедикс А/С |
Варианты альбумина
|
|
MX364438B
(es)
|
2013-03-15 |
2019-04-26 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
WO2014143659A1
(fr)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Inhibiteurs covalents irréversibles de la gtpase k-ras g12c
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
WO2015000585A1
(fr)
|
2013-07-02 |
2015-01-08 |
Walter Sebald |
Mutéines de cytokines de la famille des récepteurs de la chaîne gamma conjuguées à un groupe non protéine
|
|
GB201312059D0
(en)
|
2013-07-05 |
2013-08-21 |
Univ Leuven Kath |
Novel GAK modulators
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
UA119971C2
(uk)
|
2013-10-10 |
2019-09-10 |
Араксіс Фарма Ллк |
Інгібітори g12c kras
|
|
AR098003A1
(es)
*
|
2013-10-10 |
2016-04-27 |
Araxes Pharma Llc |
Inhibidores de kras g12c
|
|
GB201320729D0
(en)
*
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
KR101922317B1
(ko)
|
2014-01-20 |
2018-11-26 |
클리브 바이오사이언스 인코포레이티드 (클리브) |
p97 복합체의 저해제로서 융합된 피리미딘
|
|
JP6416926B2
(ja)
|
2014-02-19 |
2018-10-31 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
ガン標的化ｉｌ−１２免疫療法
|
|
WO2016035008A1
(fr)
|
2014-09-04 |
2016-03-10 |
Lupin Limited |
Dérivés de pyridopyrimidine utilisés comme inhibiteurs de mek
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
WO2016049565A1
(fr)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Compositions et procédés pour inhiber la ras
|
|
WO2016049568A1
(fr)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Méthodes et compositions permettant l'inhibition de la ras
|
|
US9862701B2
(en)
|
2014-09-25 |
2018-01-09 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EA201792214A1
(ru)
*
|
2015-04-10 |
2018-01-31 |
Араксис Фарма Ллк |
Соединения замещенного хиназолина
|
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
|
|
MX388781B
(es)
|
2015-07-22 |
2025-03-20 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituido y su uso como inhibidores de proteínas kras, hras y/o nras mutantes g12c.
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究（慕尼黑）公司 |
Dll3及cd3抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058915A1
(fr)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibiteurs de protéines mutantes kras g12c
|
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058768A1
(fr)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibiteurs de protéines kras portant la mutation g12c
|
|
EP3356354A1
(fr)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibiteurs de protéines kras portant la mutation g12c
|
|
WO2017058728A1
(fr)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibiteurs de protéines kras portant la mutation g12c
|
|
EP3356347A1
(fr)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibiteurs de protéines kras portant la mutation g12c
|
|
CA3005089A1
(fr)
*
|
2015-11-16 |
2017-05-26 |
Araxes Pharma Llc |
Composes quinazoline substitues en position 2 comprenant un groupe heterocyclique substitue et leur methode d'utilisation
|
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
BR112018012801B1
(pt)
|
2015-12-22 |
2024-03-12 |
Regeneron Pharmaceuticals, Inc |
Usos de uma combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 e de uma composição farmacêutica
|
|
US10626377B2
(en)
|
2016-01-08 |
2020-04-21 |
Replimune Limited |
Use of an oncolytic virus for the treatment of cancer
|
|
SG11201805770UA
(en)
|
2016-02-03 |
2018-08-30 |
Amgen Res Munich Gmbh |
BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
|
|
LT3411404T
(lt)
|
2016-02-03 |
2022-12-27 |
Amgen Research (Munich) Gmbh |
Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
|
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
SG11201808622SA
(en)
|
2016-04-01 |
2018-10-30 |
Amgen Inc |
Chimeric receptors to flt3 and methods of use thereof
|
|
JP6802275B2
(ja)
|
2016-04-22 |
2020-12-16 |
イムヴィラ・カンパニー・リミテッドＩｍｍｖｉｒａ Ｃｏ．， Ｌｉｍｉｔｅｄ |
癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス（ｏＨＳＶ）偏性ベクター及びその構築体の構築
|
|
AU2017266911B2
(en)
|
2016-05-18 |
2021-09-02 |
Array Biopharma, Inc. |
KRas G12C inhibitors
|
|
EP3478321A4
(fr)
|
2016-06-30 |
2020-04-22 |
Oncorus, Inc. |
Administration par un virus oncolytique pseudotypé de polypeptides thérapeutiques
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
ES2972406T3
(es)
|
2016-08-01 |
2024-06-12 |
Virogin Biotech Canada Ltd |
Vectores del virus oncolítico del herpes simple que expresan moléculas estimuladoras del sistema inmunitario
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
|
|
CN110312711A
(zh)
|
2016-10-07 |
2019-10-08 |
亚瑞克西斯制药公司 |
作为ras抑制剂的杂环化合物及其使用方法
|
|
SI3558955T1
(sl)
*
|
2016-12-22 |
2021-12-31 |
Amgen Inc., |
Derivati benzizotiazola, izotiazola(3,4-b)piridina, kinazolina, ftalazina, pirido(2,3-d)piridazina in pirido(2,3-D)pirimidina, kot zaviralci KRAS G12C za zdravljenje pljučnega raka, raka trebušne slinavke ali kolorektalnega raka
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
WO2018140598A1
(fr)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Composés n-hétérocycliques fusionnés et leurs procédés d'utilisation
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
JP2020521740A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
|
|
EP3679040B1
(fr)
*
|
2017-09-08 |
2022-08-03 |
Amgen Inc. |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
JP7266043B2
(ja)
|
2018-05-04 |
2023-04-27 |
アムジエン・インコーポレーテツド |
ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
|
|
MA52496A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
MA52564A
(fr)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
|
MA52765A
(fr)
|
2018-06-01 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
US20190375749A1
(en)
|
2018-06-11 |
2019-12-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
MA51848A
(fr)
*
|
2018-06-12 |
2021-04-21 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
JP2021527687A
(ja)
|
2018-06-21 |
2021-10-14 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｏｇａ阻害剤化合物
|
|
AU2019291101A1
(en)
|
2018-06-21 |
2021-01-07 |
Janssen Pharmaceutica Nv |
OGA inhibitor compounds
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
EP3883565A1
(fr)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
WO2020156285A1
(fr)
|
2019-01-29 |
2020-08-06 |
博瑞生物医药（苏州）股份有限公司 |
Composé de benzopyridone hétérocyclique et son utilisation
|
|
EP3738593A1
(fr)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosage d'inhibiteur de kras pour le traitement de cancers
|
|
JP7092935B2
(ja)
*
|
2019-05-21 |
2022-06-28 |
アムジエン・インコーポレーテツド |
固体形態
|
|
CA3140394A1
(fr)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Formes a l'etat solide
|
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
|
US20230028414A1
(en)
|
2019-12-16 |
2023-01-26 |
Amgen Inc. |
Dosing regimen of kras g12c inhibitor
|